Industry
Biotechnology
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
Loading...
Open
1.80
Mkt cap
64M
Volume
17K
High
1.83
P/E Ratio
-6.73
52-wk high
3.35
Low
1.75
Div yield
N/A
52-wk low
0.52
Portfolio Pulse from Benzinga Newsdesk
October 07, 2024 | 10:31 am
Portfolio Pulse from Benzinga Newsdesk
September 27, 2024 | 10:34 am
Portfolio Pulse from Benzinga Newsdesk
September 25, 2024 | 1:31 pm
Portfolio Pulse from Benzinga Newsdesk
September 25, 2024 | 12:34 pm
Portfolio Pulse from Benzinga Newsdesk
August 12, 2024 | 10:55 am
Portfolio Pulse from Benzinga Newsdesk
August 09, 2024 | 8:09 pm
Portfolio Pulse from Benzinga Newsdesk
August 01, 2024 | 12:40 pm
Portfolio Pulse from Benzinga Newsdesk
June 05, 2024 | 11:02 am
Portfolio Pulse from Benzinga Newsdesk
June 03, 2024 | 12:14 pm
Portfolio Pulse from Benzinga Newsdesk
May 14, 2024 | 10:31 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.